3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
11
Active not recruiting
3
Withdrawn
1
Unknown
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
26
Melanoma
25
Stomach Neoplasms
9
Neoplasms
8
Carcinoma, Renal Cell
7
Carcinoma, Hepatocellular
6
Squamous Cell Carcinoma of Head and Neck
5
Neoplasm Metastasis
5
Hodgkin Disease
5
Breast Neoplasms
5
Triple Negative Breast Neoplasms
4
Urinary Bladder Neoplasms
3
Prostatic Neoplasms
3
Pancreatic Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Esophageal Squamous Cell Carcinoma
3
Uveal Melanoma
2
Small Cell Lung Carcinoma
2
Sarcoma
2
Recurrence
2
Mesothelioma, Malignant
2
Lymphoma, B-Cell
2
Leukemia, Myeloid, Acute
2
Gastrointestinal Neoplasms
2
Esophageal Neoplasms
2
Carcinoma, Transitional Cell
2
Carcinoma, Merkel Cell
2
Carcinoma
2
Brain Neoplasms
2
Interventions
Fluorouracil
5
Radiotherapy
3
Paclitaxel
3
Leucovorin
3
Endoscopy
3
Cisplatin
3
Oxaliplatin
2
Neoadjuvant Therapy
2
Endoscopy, Digestive System
2
Endoscopic Mucosal Resection
2
Carboplatin
2
tremelimumab
1
rucaparib
1
rubitecan
1
durvalumab
1
Taxes
1
Surveys and Questionnaires
1
Ramucirumab
1
Radiation
1
Positron Emission Tomography Computed Tomography
1
Nivolumab
1
Microarray Analysis
1
Magnetic Resonance Imaging
1
Irinotecan
1
High-Throughput Screening Assays
1
Genetic Linkage
1
Epirubicin
1
Dynamic Contrast Enhanced Magnetic Resonance Imaging
1
Drug Therapy
1
Docetaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Unknown
×
Adenocarcinoma Of Esophagus
×
Nivolumab
×
Clear all
NCT03995017
2023-02-01
RiME
University of Kansas Medical Center
Phase 1/2
Unknown
34 enrolled